Okuzono et al. [4], studying the mechanisms of TREM2 activation in AD by investigating downstream expression changes in its antibody (Hyb87), found that unlike in healthy patients, TREM2 activation is decreased in microglia and may be linked with the type 2 immune response epitomized by pathways related to IL-4, T helper type 2 cells, and thymic stromal lymphopoietin. The gene discussed is TREM2; the disease is Alzheimer disease.